Galecto, Inc. (NASDAQ:GLTO – Get Free Report) was the target of a significant decrease in short interest in the month of June. As of June 15th, there was short interest totalling 2,600 shares, a decrease of 72.0% from the May 31st total of 9,300 shares. Based on an average daily volume of 157,200 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the shares of the stock are sold short.
Analysts Set New Price Targets
Separately, Oppenheimer cut their price objective on shares of Galecto from $10.00 to $9.00 and set an “outperform” rating for the company in a research report on Monday, June 10th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $4.33.
Read Our Latest Report on Galecto
Galecto Trading Up 2.6 %
Galecto (NASDAQ:GLTO – Get Free Report) last announced its quarterly earnings data on Monday, April 29th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.21. On average, equities research analysts forecast that Galecto will post -1.06 EPS for the current fiscal year.
About Galecto
Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.
Further Reading
- Five stocks we like better than Galecto
- Which Wall Street Analysts are the Most Accurate?
- BlackBerry Stock: Strong Earnings, Profitability Challenges Ahead
- Quiet Period Expirations Explained
- Progress Software Stock Back in the Green After Beating Forecasts
- Buy P&G Now, Before It Sets A New All-Time High
- Goldman Sachs Raises Stock Target for Affirm: Key Insights
Receive News & Ratings for Galecto Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galecto and related companies with MarketBeat.com's FREE daily email newsletter.